Henry Schein (HSIC) was Downgraded by Robert W. Baird to ” Neutral” while Lowering the Price Target of the company shares to $ 164 from a previous price target of $176 . Earlier the firm had a rating of “Outperform ” on the company shares. Robert W. Baird advised their investors in a research report released on Oct 14, 2016.
Many Wall Street Analysts have commented on Henry Schein. Henry Schein was Upgraded by Goldman to ” Buy” on Oct 11, 2016. Henry Schein was Initiated by BofA/Merrill to “Buy” on Sep 12, 2016.
On the company’s financial health, Henry Schein reported $1.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Aug 4, 2016. Analyst had a consensus of $1.63. The company had revenue of $2872.60 million for the quarter, compared to analysts expectations of $2845.09 million. The company’s revenue was up 9.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.46 EPS.
Henry Schein closed down -4.41 points or -2.70% at $158.63 with 9,83,393 shares getting traded on Tuesday. Post opening the session at $164.22, the shares hit an intraday low of $158.17 and an intraday high of $164.48 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Aug 31, 2016, Paul Brons (director) sold 3,381 shares at $164.03 per share price. According to the SEC, on Jun 3, 2016, Gerald A Benjamin (EVP, Chief Admin. Officer) sold 9,991 shares at $175.07 per share price. On May 17, 2016, James A. Harding (SVP, Chief Technology Officer) sold 10,302 shares at $172.60 per share price, according to the Form-4 filing with the securities and exchange commission.
Henry Schein Inc. provides health care products and services to office-based dental animal health and medical practitioners. The Company operates its business through two segments: health care distribution and technology and value-added services. The health care distribution segment distributes consumable products laboratory products equipment repair services branded and generic pharmaceuticals vaccines surgical products diagnostic tests infection-control products and vitamins among others. The Company’s global technology and value-added services segment provides software technology and other value-added services to health care practitioners. Its offerings include practice management software systems for dental and medical practitioners and animal health clinics. Its value-added practice solutions include financial services on a non-recourse basis e-services practice technology network and hardware services as well as continuing education services for practitioners.